Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lumitrace

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ureter InjuryActive, not recruiting

Ureter InjuryPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Ureter Injury

NCT07080008

Clinical

Trials by Indication[1]

Ureter Injury1 trial

A Single Center, Open Label Pilot Study to Assess the Feasibility and Safety of Lumitrace Injection for Intraoperative Ureter Visualization Comparing White Light (WL) Fluorescence (BLUE) in Participants Undergoing Minimally Invasive Abdominopelvic Surgeries

Active, not recruiting·MMediBeacon·Phase 1·NCT07080008·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lumitrace. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lumitrace compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lumitrace. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MediBeacon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMediBeacon

Related News